Why the future of marijuana legalization remains hazy despite high public support 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Novo Nordisk and Eli Lilly are significantly lowering prices of their blockbuster obesity drugs Wegovy and Mounjaro in China, a move aimed at expanding access in one of the world’s fastest-growing weight-loss markets and staying competitive amid rising local rivalry.
Novo Nordisk confirmed it has adjusted Wegovy prices in China, though it did not disclose specific figures. However, Chinese financial media outlet Yicai reported that list prices for the two highest doses of Wegovy were reduced by as much as 48% in certain provinces. According to the report, monthly prices dropped to about 987 yuan ($141) and 1,284 yuan, based on information from local procurement authorities. The reductions were reportedly implemented in southwestern provinces including Yunnan and Sichuan.
In a statement to Reuters, Novo Nordisk said the pricing adjustment is intended to help reduce the treatment burden for patients and improve quality of life. The Danish drugmaker is aggressively expanding its footprint in emerging markets as demand for obesity treatments accelerates globally.
Eli Lilly has not officially commented, but signs of price cuts for Mounjaro are already emerging. A hospital in Nanjing announced via its WeChat account that prices would fall starting January 1. Meanwhile, Meituan’s healthcare platform listed a 10mg Mounjaro injector pen at an estimated price of around 445 yuan, sharply down from about 2,180 yuan, signaling a substantial reduction.
China represents a massive growth opportunity, with more than 65% of its 1.4 billion population projected to be overweight or obese by 2030. However, competition is intensifying. Both Novo Nordisk and Eli Lilly face pressure from domestic drugmakers such as Innovent Biologics, CSPC Pharmaceutical Group, and Hangzhou Jiuyuan Genetic Biopharmaceutical, which are developing rival weight-loss drugs.
Further competition looms as Novo’s patent on semaglutide, Wegovy’s active ingredient, is set to expire in China in 2026. The latest price cuts mirror similar moves in India and the United States, underscoring a broader shift toward affordability and cash-paying consumers in the global obesity drug market.
